Updating the Carboplatin Hypersensitivity Protocol: Two Case Studies

Carboplatin is used to treat gynecologic cancers. Reexposure to carboplatin in the recurrent disease setting increases the risk of hypersensitivity reactions, which can be mild or cause death. A carboplatin desensitization protocol was developed to help with patient tolerance, but no standard protocol existed.

This protocol was updated to replace an older desensitization protocol, align with best practices, and bring cost savings to the institution through reduced labor and shortened hospital stays.

The updated four-bag, four-hour protocol was implemented in patient care on March 8, 2024. A total of five desensitizations were completed. Each desensitization was retrospectively reviewed and assessed for safety and tolerability using the Common Terminology Criteria for Adverse Events.

Five desensitizations successfully occurred for two patients between March 8 and July 13, 2024. Each desensitization saved $108 in pharmacy supply costs and $92 in pharmacy labor costs. Saved nursing costs totaled about $400 for each desensitization.